Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply.

Subjects

Subjects :

Humans
Chemotherapy, Adjuvant
Randomized Controlled Trials as Topic
Immune Checkpoint Inhibitors
Bevacizumab therapeutic use
Antineoplastic Agents therapeutic use
Carcinoma, Hepatocellular drug therapy
Liver Neoplasms drug therapy
Antibodies, Monoclonal, Humanized therapeutic use

Details

Language :

English

ISSN :

1474-547X

Volume :

404

Issue :

10453

Database :

MEDLINE

Journal :

Lancet (London, England)

Publication Type :

Editorial & Opinion

Accession number :

39153815

Full Text :

https://doi.org/10.1016/S0140-6736(24)00801-8